Evidence map›Paper›PMID 39399196›Full record

ArticleJournal of community hospital internal medicine perspectives2024

Game Changer or More of the Same? A Comparative Meta-analysis of Rezafungin and Caspofungin in Treating Candidemia and Invasive Candidiasis.

Zouina Sarfraz, Zeeshan Nasir, Faheem Javad, Aden Khan, Bushra Shah, Musfira Khalid, Azza Sarfraz, Muzna Sarfraz, Amna Minhas, Suchal A Gondal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of community hospital internal medicine perspectives, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zouina SarfrazFatima Jinnah Medical University, Lahore, Pakistan.
Zeeshan NasirNishtar Medical University, Multan, Pakistan.
Faheem JavadAl Nafees Medical College, Islamabad, Pakistan.
Aden KhanFatima Jinnah Medical University, Lahore, Pakistan.
Bushra ShahFatima Jinnah Medical University, Lahore, Pakistan.
Musfira KhalidFatima Jinnah Medical University, Lahore, Pakistan.
Azza SarfrazThe Aga Khan University, Karachi, Pakistan.
Muzna SarfrazKing Edward Medical University, Lahore, Pakistan.
Amna MinhasFatima Jinnah Medical University, Lahore, Pakistan.
Suchal A GondalRawalpindi Medical University, Rawalpindi, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This meta-analysis assesses the recent Food and Drug Administration (FDA)-approved antifungal, rezafungin, for treating candidemia and invasive candidiasis-both are significant health concerns with limited treatment options. Two randomized controlled trials comparing rezafungin to caspofungin were meta-analyzed, revealing no significant differences in global cure rates and 30-day all-cause mortality. While rezafungin's unique attributes, like a novel mechanism and once-weekly dosing, may enhance patient adherence, concerns arise about its clinical relevance given the substantial investment. The study emphasizes the need for ongoing research, post-marketing surveillance, and real-world data to determine rezafungin's true value in managing these life-threatening fungal infections. Despite FDA approval, further investigation is warranted for a comprehensive understanding of rezafungin's efficacy and safety.

Indexed as

Antifungal therapyCandidemiaInvasive candidiasisMeta-analysisRezafungin

Identifiers

PMID39399196
PMCPMC11466332

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.